Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Open Access
- 15 October 2005
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 106 (8), 2865-2870
- https://doi.org/10.1182/blood-2005-04-1568
Abstract
The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation. We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM. The patient exhibited a partial response with significant resolution of liver function abnormalities. In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency. The patient died after 3 months of therapy due to progression of her MDS/MPD to acute myeloid leukemia (AML). This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease. (Blood. 2005; 106:2865-2870)Keywords
This publication has 26 references indexed in Scilit:
- Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412Blood, 2005
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Published by American Society of Hematology ,2005
- Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patientsBritish Journal of Haematology, 2002
- Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412Cancer Cell, 2002
- The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutationsBlood, 2002
- Serum Tryptase Measurements in Patients with Myelodysplastic SyndromesLeukemia & Lymphoma, 2002
- The Complexity of KIT Gene Mutations and Chromosome Rearrangements and Their Clinical Correlation in Gastrointestinal Stromal (Pacemaker Cell) TumorsThe American Journal of Pathology, 2002
- Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit–mediated cytokine-independent survival and proliferation in human leukemia cellsBlood, 2001
- Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase CJournal of Clinical Oncology, 2001
- PKC412--a protein kinase inhibitor with a broad therapeutic potential.2000